AbbVie (ABBV) announced that it has submitted an application to the U.S. FDA seeking approval for Skyrizi for subcutaneous induction for the treatment of adult patients with moderately to severely active Crohn’s disease.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Options Volatility and Implied Earnings Moves This Week, April 27 – May 01, 2026
- Is ABBV a Buy, Before Earnings?
- AbbVie Completes Early ABBV-722 Tablet Study, Offering a Small Boost to Pipeline Visibility
- CrowdStrike, ADMA, Achieve, AbbVie, Valero Trending With Analysts
- AbbVie receives CRL from FDA regarding BLA for trenibotulinumtoxinE